Drug Discovery by Molecular Imaging and Monitoring Therapy Response in Lymphoma
Molecular imaging allows a noninvasive assessment of biochemical and biological processes in living subjects. Treatment strategies for malignant lymphoma depend on histology and tumor stage. For the last two decades, molecular imaging has been the mainstay diagnostic test for the staging of malignan...
Main Authors: | Senthilkumar Kalimuthu, Ju Hye Jeong, Ji Min Oh, Byeong-Cheol Ahn |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-07-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/18/8/1639 |
Similar Items
-
FDG-PET/CT in lymphoma
by: Maria M D′souza, et al.
Published: (2013-10-01) -
FDG-PET/CT in lymphoma
by: Maria M D′souza, et al.
Published: (2013-01-01) -
PET/CT in initial staging and therapy response assessment of lymphoma
by: Nagham Nabil Omar, et al.
Published: (2016-12-01) -
Neurolymphomatosis: Unusual Extranodal Involvement Pattern on 18F-FDG PET/CT in a Non-Hodgkin Lymphoma Recurrence
by: Marcos Pretto Mosmann, et al.
Published: (2011-04-01) -
Clinical usefulness of PET-CT in staging, evaluation of treatment response and restaging of thoracic lymphoma
by: Ahmed Elsammak
Published: (2017-12-01)